Storey RF - Search Results

1

Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy.

Nelson TA, Parker WAE, Ghukasyan Lakic T, Westerbergh J, James SK, Siegbahn A, Becker RC, Himmelmann A, Wallentin L, Storey RF. Nelson TA, et al. Among authors: storey rf. Platelets. 2022 Apr 3;33(3):425-431. doi: 10.1080/09537104.2021.1934667. Epub 2021 Jun 2. Platelets. 2022. PMID: 34077291 Clinical Trial.

2

Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.

Storey RF, Wilcox RG, Heptinstall S. Storey RF, et al. Platelets. 2002 Nov;13(7):407-13. doi: 10.1080/0953710021000024402. Platelets. 2002. PMID: 12487788 Clinical Trial.

3

Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.

Smith SM, Judge HM, Peters G, Storey RF. Smith SM, et al. Among authors: storey rf. Platelets. 2004 Dec;15(8):465-74. doi: 10.1080/0953710412331272532. Platelets. 2004. PMID: 15763887

4

PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.

Smith SM, Judge HM, Peters G, Armstrong M, Dupont A, Gaussem P, Storey RF. Smith SM, et al. Among authors: storey rf. Platelets. 2005 Sep;16(6):340-5. doi: 10.1080/00207230500120294. Platelets. 2005. PMID: 16194864

5

Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.

Judge HM, Buckland RJ, Holgate CE, Storey RF. Judge HM, et al. Among authors: storey rf. Platelets. 2005 Nov;16(7):398-407. doi: 10.1080/09537100500163226. Platelets. 2005. PMID: 16236601

6

Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.

Smith SM, Judge HM, Peters G, Armstrong M, Fontana P, Gaussem P, Daly ME, Storey RF. Smith SM, et al. Among authors: storey rf. Platelets. 2006 Jun;17(4):250-8. doi: 10.1080/09537100500475844. Platelets. 2006. PMID: 16769602 Clinical Trial.

7

The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.

Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. Judge HM, et al. Among authors: storey rf. Platelets. 2008 Mar;19(2):125-33. doi: 10.1080/09537100701694144. Platelets. 2008. PMID: 18297550

8

Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development.

Kleiman NS, Freedman JE, Tracy PB, Furie BC, Bray PF, Rao SV, Phillips DR, Storey RF, Rusconi CP, French PA, Steinhubl SR, Becker RC. Kleiman NS, et al. Among authors: storey rf. Platelets. 2008 Jun;19(4):239-51. doi: 10.1080/09537100801947442. Platelets. 2008. PMID: 18569859 Review.

9

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. James S, et al. Among authors: storey rf. Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003. Am Heart J. 2009. PMID: 19332184 Clinical Trial.

10

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

APPRAISE Steering Committee and Investigators; Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F, Wallentin L. APPRAISE Steering Committee and Investigators, et al. Circulation. 2009 Jun 9;119(22):2877-85. doi: 10.1161/CIRCULATIONAHA.108.832139. Epub 2009 May 26. Circulation. 2009. PMID: 19470889 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

399 results

Search Page